PubRank

Michael E Brune

Author PubWeight™ 19.29‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. J Med Chem 2008 1.30
2 Effects of substitution on 9-(3-bromo-4-fluorophenyl)-5,9-dihydro-3H,4H-2,6-dioxa-4- azacyclopenta[b]naphthalene-1,8-dione, a dihydropyridine ATP-sensitive potassium channel opener. J Med Chem 2006 1.23
3 Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1. J Med Chem 2012 0.94
4 Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors. J Med Chem 2007 0.88
5 Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists. Expert Opin Investig Drugs 2005 0.85
6 Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a potent K(ATP) opener that selectively inhibits spontaneous bladder contractions. J Med Chem 2004 0.84
7 Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists. J Med Chem 2006 0.83
8 2,4-diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonists. J Med Chem 2006 0.83
9 Acute inhibition of 11beta-hydroxysteroid dehydrogenase type-1 improves memory in rodent models of cognition. J Neurosci 2011 0.83
10 Chronic treatment with either dexfenfluramine or sibutramine in diet-switched diet-induced obese mice. Endocrine 2006 0.79
11 Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists. J Pharmacol Exp Ther 2002 0.79
12 Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety. Eur J Pharmacol 2006 0.79
13 Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing alpha(1A)-adrenoceptor agonist. J Med Chem 2004 0.78
14 Effects of ATP-sensitive K+ channel openers and tolterodine on involuntary bladder contractions in a pig model of partial bladder outlet obstruction. Neurourol Urodyn 2003 0.78
15 Structure-activity relationship of a novel class of naphthyl amide KATP channel openers. Bioorg Med Chem Lett 2003 0.78
16 Differential effects of Vitamin D analogs on bone formation and resorption. J Steroid Biochem Mol Biol 2005 0.78
17 Structure-activity studies of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder. J Med Chem 2007 0.77
18 Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity. Bioorg Med Chem Lett 2005 0.76
19 Preclinical pharmacology of fiduxosin, a novel alpha(1)-adrenoceptor antagonist with uroselective properties. J Pharmacol Exp Ther 2002 0.76
20 K-ATP opener-mediated attenuation of spontaneous bladder contractions in ligature-intact, partial bladder outlet obstructed rats. Life Sci 2003 0.76
21 Pharmacological characterization of urinary bladder smooth muscle contractility following partial bladder outlet obstruction in pigs. Eur J Pharmacol 2006 0.75
22 Constrained 7-fluorocarboxychromone-4-aminopiperidine based Melanin-concentrating hormone receptor 1 antagonists: the effects of chirality on substituted indan-1-ylamines. Bioorg Med Chem Lett 2006 0.75
23 In vitro and in vivo characterization of a novel naphthylamide ATP-sensitive K+ channel opener, A-151892. Br J Pharmacol 2004 0.75
24 N-[3-(1H-imidazol-4-ylmethyl)phenyl]ethanesulfonamide (ABT-866, 1),(1) a novel alpha(1)-adrenoceptor ligand with an enhanced in vitro and in vivo profile relative to phenylpropanolamine and midodrine. J Med Chem 2002 0.75
25 Pharmacological characterization of the novel dihydropyridine potassium channel opener, (9R)-9-(3-iodo-4-methylphenyl)-5,9-dihydro-3H-furo[3,4-b]pyrano[4,3-e]pyridine-1,8(4H,7H)-dione (A-325100), and the regulation of cardiovascular function in conscious and anesthetized beagle dogs. J Cardiovasc Pharmacol 2005 0.75